Last Updated: November 18, 2020


Featured Articles

Novel Antiretroviral Agents

Current HIV/AIDS Reports Feb 2020

TAG’s 2019 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | July 2019

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | December 2018

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | October 25, 2018

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
News Updates

Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications 

Afr Health Sci. 2020 Jun;20(2):597-604. doi: 10.4314/ahs.v20i2.7.

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Merck | November 16, 2020

Changes to SELZENTRY (maraviroc) labeling to include safety and PK data in pediatric patients weighing at least 2 kg

FDA | November 2, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV | October 17, 2020

Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV | October 16, 2020

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment 

POZ | October 16, 2020

Gilead's Biktarvy sustains viral suppression and tolerability in Asian HIV patients 

BSA bureau | October 15, 2020

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel

Journal of the American Medical Association | October 14, 2020

Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In 

POZ | October 9, 2020

Dentists, do you know which drugs do not mix with remdesivir?

Dr Bicuspid | October 8, 2020

Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified | October 8, 2020

HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function

POZ | October 7, 2020

Injectable HIV therapy should save money if adherence is better than to oral therapies 

aidsmap | October 7, 2020

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial 

PubMed | 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1

Gilead's Truvada faces Teva generics assault amid Descovy switching campaign 

FiercePharma | October 2, 2020

ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices

ViiV Healthcare | September 28, 2020

Pharmacists Play a Critical Role in Managing Changes to HIV Care During COVID-19 

Pharmacy Times | September 16, 2020

Integrase Inhibitors Tied to Fewer Potentially Harmful Drug Interactions

POZ | August 31, 2020

FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling

FDA | August 6, 2020

Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial 

Antimicrob Agents Chemother. 2020 Aug 3;AAC.00838-20. doi: 10.1128/AAC.00838-20

PREZCOBIX and EVOTAZ: Pediatric Label Updates

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The Lancet | July 25, 2020

EPCLUSA: updates to labeling (liver transplant)

Long-acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study

NIH | July 7, 2020

Dolutegravir Use at Conception Not Tied to Neural Tube Defects After All

POZ | July 7, 2020

The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection

AIDS 2020: 23rd International AIDS Conference Virtual, July 6-10, 2020

HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men

IAC 2020 July 6-10 Virtual SF

New Findings on Gilead's Biktarvy Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults | July 4, 2020

Clinical targeting of HIV capsid protein with a long-acting small molecule

Nature. 2020 Jul 1. doi: 10.1038/s41586-020-2443-1

New Data Shows Promise Involving Lenacapavir for the Treatment of HIV 

BioSpace | July 2, 2020

Treatment Action Group’s 2020 HIV Pipeline Report 

TAG | July 2020

RUKOBIA: New Drug Approved for HIV-1

FDA | July 2020

FDA expands Gardasil 9 approval for head and neck cancer prevention

Healio | June 15, 2020

Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research

Expert Opin Drug Deliv. 2020 Jun 17. doi: 10.1080/17425247.2020.1783233

FDA expands Gardasil 9 approval for head and neck cancer prevention

Healio | June 15, 2020

FDA Approves Drug to Treat Infants and Children with HIV

FDA | June 12, 2020

Safety highlights from the DISCOVER Trial

Gilead | June 2020

Trivicay Now Available for Babies as Young as 4 Weeks

Infectious Disease Special Edition | June 12, 2020

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2020 Annual Report

NASTAD | June 5, 2020

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

NIH | May 22, 2020

New COVID-19 CDC Resources on PrEP and Liver Disease | May 21, 2020

NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men, and Transgender Women | May 18, 2020

HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe 

Infectious Disease Advisor | May 7, 2020

FDA authorizing the emergency use of remdesivir for treatment of COVID-19

Updated 2020 National AIDS Drug Assistance Program (ADAP) Formulary Database

NASTAD | April 2020

NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate

NIH | April 2, 2020

Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection

NCBI | March 2020

ADAP Advocacy Association Applauds Pharmaceutical Industry Efforts on Protecting the Drug Supply Chain during the Coronavirus Pandemic 

ADAP Advocacy Association | March 26, 2020

ViiV Healthcare on Friday announced that Health Canada has approved Cabenuva (cabotegravir and rilpivirine)

The Pharma Letter | March 21, 2020

EPCLUSA: Labeling Updates for Pediatric Patients

FDA | March 19, 2019

Newer anti-HIV drugs safest, most effective during pregnancy

NIH | March 11, 2020


CROI 2020 March 11

New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults

Gilead Sciences, Inc | March 9, 2020

ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

ViiV | March 9, 2020

Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV

CROI 2020, March 8-11, 2020, Boston

Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch

CROI 2020, March 8-11, 2020, Boston

F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks

CROI 2020, March 8-11, 2020, Boston

Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP

CROI 2020, March 8-11, 2020, Boston

Maraviroc Does Not Demonstrate Clinical Benefit in Advanced HIV 

Infectious Disease Advisor | March 5, 2020

SYMTUZA: Pediatric Labeling Updates

FDA | March 4, 2020

Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach

The New England Journal of Medicine | March 4, 2020

Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

Gilead Sciences, Inc | November 8, 2019

A Secure Drug Supply Chain is the Best Anti-Counterfeiting Technology We Have

ADAP Advocacy Association | February 27, 2020

Rockefeller grants commercial license for the development of new HIV drugs

Rockerfeller | February 26, 2020

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.

Adding maraviroc to standard treatment for advanced HIV does not improve outcomes 

Healio | February 10, 2020

Just one dose of HPV vaccine may confer durable cervical cancer protection

Healio | February 10, 2020

AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis

abbvie | January 31, 2020

VEMLIDY: Labeling Updates

FDA | February 4, 2020

Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016

CDC | January 31, 2020

A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)

NATAP | January 2020

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

ViiV Healthcare | London, 10 January 2020

Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2020

FDA Programs to Register HIV Drugs for Use in Resource-Constrained Settings 

Infectious Disease Advisor | January 3, 2020

Following backlash, Facebook disables misleading HIV medication ads

Dec. 30, 2019, 3:44 PM EST

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid Initiation Model of Care for HIV-1 Infection: Primary Analysis of the DIAMOND Study

Clinical Infectious Diseases 27 December 2019

What's New in the Guidelines?

aidsinfo | December 2019

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

ViiV Healthcare | December 21, 2019

Prescribing practices for pregnant women with HIV not aligned with guidelines 

Healio | December 18, 2019

Facebook ads are spreading lies about anti-HIV drug PrEP. The company won't act 

The Guardian | December 14, 2019

Cost prevents 7% of people will HIV from adhering to medication 

Healio | December 12, 2019

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Viiv | December 5, 2019

HARVONI, EPCLUSA, and VOSEVI Labeling updates: HCV-infected adults with severe renal impairment

FDA | November 18, 2019

CDC Antibiotic Resistance: New Threats Report

Understanding the Medicaid Prescription Drug Rebate Program – Kaiser Family Foundation

KFF | November 12, 2019

Untangling the Trump administration's lawsuit over an HIV prevention drug 

Science Magazine | November 8, 2019

Facts About Gilead’s PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts

NATAP | November 4, 2019 at 12:01:02 PM EST

Gilead Perspective on HHS Lawsuit

The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV

17th European AIDS Conference, November 6-9, 2019, Basel

Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort

17th European AIDS Conference, November 6-9, 2019, Basel

INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure

17th European AIDS Conference, November 6-9, 2019, Basel

Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys

17th European AIDS Conference, November 6-9, 2019, Basel

DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate

17th European AIDS Conference, November 6-9, 2019, Basel

Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

Gilead | November 8, 2019

BARACLUDE: Updates to Adverse Reactions from Long-Term Observational Study

FDA | November 8, 2019

Label updates to efavirenz containing products

FDA | October 30, 2019

Hepatitis C Treatments Are Safe and Effective for Seniors

POZ | October 28, 2019

Dolutegravir and risk of neural tube defects: Labeling Updates

FDA | October 25, 2019

Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work

The Body Pro | October 16, 2019

Rapid ART Initiation: A New Model Presents Unique Opportunities and Challenges | October 11, 2019

The 8th World Workshop on Oral Health and Disease in AIDS

BRITISH DENTAL JOURNAL | VOLUME 227 NO. 7 | October 11 2019

Photos courtesy of Dr. David Croser

IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

ViiV Healthcare | October 2, 2019

MAVYRET: new dosage regimen and labeling updates

FDA | October 1, 2019

FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options

NATAP | September 26, 2019

Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed

Business Wire | September 20, 2019

Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV

Yahoo Finance | September 19, 2019

FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease

FDA | August 28, 2019

ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

GSK | August 22, 2019

Extensive Drug Resistance Has Become Rare Among People With HIV

POZ | August 19, 2019

FDA panel backs Gilead's HIV prevention drug for certain population

Reuters | August 7, 2019

BIKTARVY: recent changes to labeling

FDA | August 6, 2019

ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational ... 

Yahoo Finance | July 29, 2019

WHO Recommends Antiretroviral Drug Dolutegravir As Preferred HIV Treatment, Including For ... 

Kaiser Family Foundation | July 23, 2019

Folic acid reduces risk of neural tube defects linked to HIV drug dolutegravir

EurekAlert | July 23, 2019

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

The Lancet | July 12, 2019

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 

aidsinfo | July 10, 2019

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

BioSpace | July 10, 2019

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

ViiV Healthcare | July 10, 2019

GSK's Dovato suppresses AIDS virus at same levels of three-drug regimen 

Reuters | July 10, 2019

Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

BioSpace | July 9, 2019

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

ViiV Healthcare | July 8, 2019

TRUVADA: Important Updates to the REMS

FDA: HIV Email Updates | July 1, 2019

Long-Acting Antiretrovirals for Treatment 

NASTAD | June 26, 2019

HIV Updates: BIKTARVY label revisions

HIV drug cabotegravir not associated with weight gain

Healio | June 8, 2019

AIDS groups criticize Express Scripts for excluding several HIV medicines

STAT | June 6, 2019

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2019 Annual Report

NASTAD | June 6, 2019

Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Baseline genotype testing at HIV diagnosis not cost-effective

Healio | May 13, 2019

Gilead to Donate Up to 2.4M Bottles of HIV Prevention Pills Each Year in the U.S.

POZ | May 10, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

NIH | May 9, 2019

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet | May 5, 2019

ViiV Healthcare seeks FDA approval for long-term injectable HIV treatment

WRAL Tech Wire | April 29, 2019

MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication

AIDS Behav. 2018 Apr;22(4):1158-1164. doi: 10.1007/s10461-017-1972-6

Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591

NATAP | April 10, 2019

NATAP: HIV-Drug Resistance Testing/DHHS Guidelines

Last Updated: October 25, 2018

ViiV Healthcare Announces CHMP Positive Opinion for DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) as a Once-Daily, Single-Pill, Two-Drug Reimen for the Treatment of HIV Infection

ViiV | April 26, 2019

New Rule at Centers for Medicare and Medicaid Helps Lower Costs of Meds

POZ | April 23, 2019

Special thanks to The AIDS Institute for leading the charge on this important issue

Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

NATAP | April 18, 2019

FDA Has Approved New Two-Drug Regimen to Treat People with HIV

Healthline | April 15, 2019

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

Janssen | April 11, 2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA | April 8, 2019

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Market Watch |  Apr 9, 2019

Pharma giant profits from HIV treatment funded by taxpayers and patented by the government

Washington Post | March 26, 2019

Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model

Gilead | March 26, 2019

Long-acting injectable treatment maintains viral suppression

aidsmap | March 8, 2019

Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable

Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle

Integrase inhibitor treatment leads to greater weight gain

aidsmap | March 7, 2019

ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection

ViiV | March 7, 2019

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

AIDS: March 1, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead | February 11, 2019

Acyclovir labeling now includes details for treating premature infants infected with herpes virus

NIH | February 8, 2019

FDA Hepatitis Update- VEMLIDY labeling revised (renal information)

FDA | February 6, 2019

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

University of Nebraska Medical Center | December 21, 2018

Note from Dr. Reznik – This information is valuable for oral infections with Candida glabrata


FDA | December 11, 2018

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet | November 9, 2018

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov

FDA HIV Update: GENVOYA, STRIBILD, and TYBOST Pregnancy Label

FDA | November 7, 2018

Novel antibiotic shows promise in treatment of uncomplicated gonorrhea

NIH | November 7, 2018

NASTAD Announces the Release of

NASTAD | November 6, 2018

Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)

NATAP | November 6, 2018

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than ...

aidsmap | November 2018

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients ...

aidsmap | November 2, 2018

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

aidsmap | November 1, 2018

FDA HIV Update- ODEFSEY/COMPLERA: Pregnancy Label Updates

FDA | October 31, 2018

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Outcomes of Patients Not Achieving Primary Endpoint From an Ibalizumba Phase 3 Trial

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Bictegravir/F/TAF Noninferior to DTG Plus F/TAF at 96 Weeks: No Resistance
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow